| Project/Area Number |
25460455
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHINTANI Michiko (TANAKA Michiko) 神戸大学, 大学院保健学研究科, 助教 (40207147)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YOSHIKAWA Takaki 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター, 消化器外科, 医長 (30336573)
|
|---|
| Research Collaborator |
NAKA Ayano
TAKEDA Risa
OGANE Naoki
KAMEDA Yoichi
AOYAMA Toru
SHIMAKATA Takaaki
KAWAMURA Jumpei
DENDA Tamami
KAWAI Kenji
KUWAO Sadahito
YANAGITA Emmy
ITOH Tomoo
SAKAMAKI Kuniko
HAYASHI Yurie
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 胃癌 / 化学療法 / 効果予測 / SLCトランスポーター / 免疫組織化学 |
|---|
| Outline of Final Research Achievements |
First, we evaluated OCT2 expression in advanced gastric cancers (GCs) treated with neoadjuvant chemotherapy (NAC) with S-1/cisplatin. Expression levels of OCT2 were immunohistochemically assessed and correlated with pathologic response. The rate of high expression levels of OCT2 (OCT2High) was significantly higher in responders compared with non-responders. In addition, OCT2High was the sole independent predictor of response. These results suggest that OCT2High may represent a potential predictor of response to NAC with S-1/cisplatin in GC.
Next, we evaluated expression levels of a panel of SLC transporters in α-fetoprotein (AFP)-producing GCs and conventional GCs. The rates of high expression levels of ENT1 (ENT1High) and OAT2 (OAT2High) were statistically higher in AFP-producing GCs compared with conventional GCs. These results suggest that patients with AFP-producing GC could potentially benefit from gemcitabine/fluoropyrimidine combination chemotherapy.
|
